Skip to content
City AM
Main navigation
Download free app
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Insurance
      • Square Mile and me
      • Tech
      • Legal
      • Banking
      • Property
      • Retail
      • Crypto
      • Transport
    • From our partners
      • AON
      • Tottenham Hotspur Stadium
      • Eastern City BID
      • London Stansted Airport
      • YourCause from Blackbaud
      • Inside Saudi
      • Central London Alliance CIC
    • Featured

      test_editor

      The owner of Ray-Ban has issued a warning. (Photo by Sergio Albert/Ray-Ban via Getty Images)

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
      • The Punter
    • From our partners
      • The Morning Briefing: SBS x City AM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Premiership run-in: Saints and Bath will impact top four

      2Look at the Premiership table and you’ll see that the top team and Challenge Cup finalists Bath are 15 points clear of second-placed Leicester Tigers, and Champions Cup finalists Northampton Saints are 17 points safe from dropping out of the top eight.

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Life&Style
    • Life&Style
      • Life&Style
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • The King’s Awards 2024
    • Featured

      Here We Are, National Theatre, review: Stephen Sondheim musical is more Severance than sing-a-long

      Rory Kinnear and Jane Krakowski lead the cast in Here We Are, the final show with music from the composer Stephen Sondheim (Photo: Marc Brenner)

      Submit a story

      Tell us your story.

      Submit
  • Latest Paper
  • Personal Finance
  • CityAM Awards
  • Sign In
  • Sign Out
  • My Account

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong.

Take 2 mins to learn more at www.coinbase.com/uk-fca-info

GSK

  • GSK shares rise after £1.7bn Zantac settlement

    pharma

    GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]

    GSK higher after settling Zantac cases
  • Pharma giants GSK, Pfizer and Sanofi granted supreme court hearing in Zantac cancer lawsuits

    pharma

    Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits alleging that the now-discontinued heartburn drug Zantac caused cancer. The companies, which also include Pfizer and Sanofi, are challenging a lower court ruling that allowed expert testimony claiming Zantac causes cancer – a link [...]

    GSK higher after settling Zantac cases
  • GSK receives US breakthrough therapy designation for lung cancer treatment

    pharma

    Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]

    GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.
  • GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer

    August 6, 2024

    GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.

  • GSK: Pharma giant raises guidance after second quarter sales give shot in the arm

    July 31, 2024

    London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 reached £7.9bn, an increase of 13 per cent year on year. Core operating profit at the pharma company rose by 18 per cent on [...]

  • Consumer confidence hit highest level in three years

    July 19, 2024

    Consumer confidence has risen to its highest level in three years in a tentative sign that the economy is leaving the cost-of-living crisis behind, new data from Deloitte shows. In its latest quarterly Consumer Tracker survey, Deloitte found that sentiment grew by 6.8 per cent year on year, boosted by a significant improvement in sentiment [...]

  • GSK moves into New Oxford Street office in boost for central London

    July 16, 2024

    GSK has opened the doors to its new West End office - called the Earnshaw.

  • GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines

    July 3, 2024

    GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.

  • US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots

    June 25, 2024

    Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.

  • Election 2024: Firms have ‘nothing to worry about’ on workers’ rights, Reeves says

    June 21, 2024

    Rachel Reeves has told businesses they have “nothing to worry about” from Labour’s workers' rights reforms at The Times CEO Summit.

Posts pagination

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 19
  • Next

Trending Articles

  • ACA Launches Comprehensive Market Abuse Risk Framework for Buy-Side Firms

  • Factory output keep sliding as China struggles to find growth

  • Firms too vulnerable to defaults

  • ‘I’ve directed Sir David Attenborough for 40 years – these are my best stories’

  • The new A-Class really is all class

  • RAPID responses

  • Restructurings to continue…

  • SFO drops prosecution of biotech millionaire Sir Christopher Evans

  • England’s Test and Trace system misses one in four people with coronavirus

  • Asset managers call on index providers to drop controversial weapons firms

Subscribe

Subscribe to the City AM newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Careers
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • News
  • Markets & Economics
  • Opinion
  • Life&Style
  • Personal Finance
  • Got a story?
  • The Punter
  • City AM Curated
  • Wine
  • Casino

Follow us for breaking news and latest updates

  • Facebook
  • X
  • Instagram
  • LinkedIn
  • Newsletters
  • Advertising
  • About
  • Tickets
Copyright 2025 City AM Limited